{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:50:11Z","timestamp":1783457411477,"version":"3.55.0"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"08","funder":[{"name":"Broxmeyer Fellowship in Clinical Thrombosis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-\/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)\u2014the combination of low-dose anticoagulants with antiplatelet agents\u2014to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens\u2014mostly rivaroxaban and aspirin\u2014in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis\u2014and thus maximize safety\u2014should be assessed in appropriate populations.<\/jats:p>","DOI":"10.1055\/a-1778-1083","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:19:05Z","timestamp":1645489145000},"page":"1279-1287","source":"Crossref","is-referenced-by-count":14,"title":["State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism"],"prefix":"10.1055","volume":"122","author":[{"given":"Mark","family":"Goldin","sequence":"additional","affiliation":[{"name":"Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States"},{"name":"Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Koulas","sequence":"additional","affiliation":[{"name":"Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada"},{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[{"name":"Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States"},{"name":"Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, United States"},{"name":"Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"issue":"S 02","key":"ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2002-32312","article-title":"Venous thromboembolism epidemiology: implications for prevention and management","volume":"28","author":"J A Heit","year":"2002","journal-title":"Semin Thromb Hemost"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jama.1997.03540320044033","article-title":"A prospective study of risk factors for pulmonary embolism in women","volume":"277","author":"S Z Goldhaber","year":"1997","journal-title":"JAMA"},{"issue":"16","key":"ref3","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/archinte.159.16.1886","article-title":"Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: \u201cthe study of men born in 1913\u201d","volume":"159","author":"P O Hansson","year":"1999","journal-title":"Arch Intern Med"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1538-7836.2006.02132.x","article-title":"The metabolic syndrome and the risk of venous thrombosis: a case-control study","volume":"4","author":"W Ageno","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","article-title":"A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study","volume":"151","author":"F A Anderson Jr","year":"1991","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2796.1992.tb00565.x","article-title":"A prospective study of the incidence of deep-vein thrombosis within a defined urban population","volume":"232","author":"M Nordstr\u00f6m","year":"1992","journal-title":"J Intern Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/archinte.1994.00420020066008","article-title":"Acquired risk factors for deep-vein thrombosis in symptomatic outpatients","volume":"154","author":"A Cogo","year":"1994","journal-title":"Arch Intern Med"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2168.1999.01129.x","article-title":"Deep venous thrombosis in peripheral vascular disease","volume":"86","author":"G Libertiny","year":"1999","journal-title":"Br J Surg"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2141.2002.03563.x","article-title":"Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors","volume":"118","author":"A Vay\u00e1","year":"2002","journal-title":"Br J Haematol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"W Ageno","year":"2008","journal-title":"Circulation"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa022157","article-title":"An association between atherosclerosis and venous thrombosis","volume":"348","author":"P Prandoni","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1161\/01.ATV.19.12.3007","article-title":"Age and sex differences in the distribution and ultrasound morphology of carotid atherosclerosis: the Troms\u00f8 Study","volume":"19","author":"O Joakimsen","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.STR.30.4.841","article-title":"Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study","volume":"30","author":"S Ebrahim","year":"1999","journal-title":"Stroke"},{"issue":"24","key":"ref14","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1161\/01.CIR.0000018650.58984.75","article-title":"Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study","volume":"105","author":"M Hollander","year":"2002","journal-title":"Circulation"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/eurheartj\/ehi018","article-title":"A prospective study on cardiovascular events after acute pulmonary embolism","volume":"26","author":"C Becattini","year":"2005","journal-title":"Eur Heart J"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"S Schulman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1538-7836.2006.02058.x","article-title":"Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis","volume":"4","author":"P Prandoni","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(07)61745-0","article-title":"Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study","volume":"370","author":"H T S\u00f8rensen","year":"2007","journal-title":"Lancet"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"D L Bhatt","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"P G Steg","year":"2007","journal-title":"JAMA"},{"issue":"19","key":"ref21","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry","volume":"30","author":"M J Alberts","year":"2009","journal-title":"Eur Heart J"},{"issue":"09","key":"ref22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"V Aboyans","year":"2018","journal-title":"Eur Heart J"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1074248415578172","article-title":"Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies","volume":"20","author":"E Perzborn","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty","volume":"378","author":"D R Anderson","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"ref25","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"ref26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"J Simes","year":"2014","journal-title":"Circulation"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"J L Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"ref28","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.jacc.2020.04.071","article-title":"Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients","volume":"75","author":"A C Spyropoulos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"M P Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"D A Morrow","year":"2012","journal-title":"N Engl J Med"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14779072.2020.1806712","article-title":"Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review","volume":"18","author":"E Parascandolo","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"15","key":"ref33","doi-asserted-by":"crossref","first-page":"99329","DOI":"10.1172\/jci.insight.99329","article-title":"Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis","volume":"3","author":"D Hanjaya-Putra","year":"2018","journal-title":"JCI Insight"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"J W Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"J L Mega","year":"2009","journal-title":"Lancet"},{"issue":"20","key":"ref36","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"P G Steg","year":"2011","journal-title":"Eur Heart J"},{"issue":"22","key":"ref37","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"J H Alexander","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jacc.2019.07.065","article-title":"Major bleeding in patients with coronary or peripheral artery disease treated with rivaroxaban plus aspirin","volume":"74","author":"J W Eikelboom","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"A T Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/CIRCULATIONAHA.116.025427","article-title":"Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX Trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)","volume":"135","author":"C M Gibson","year":"2017","journal-title":"Circulation"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"e006015","DOI":"10.1161\/JAHA.117.006015","article-title":"Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy","volume":"6","author":"C M Gibson","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"A C Spyropoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1076029619886022","DOI":"10.1177\/1076029619886022","article-title":"Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN Study","volume":"25","author":"A C Spyropoulos","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"22","key":"ref46","doi-asserted-by":"crossref","first-page":"e021579","DOI":"10.1161\/JAHA.121.021579","article-title":"Benefit-risk of rivaroxaban for extended thromboprophylaxis after hospitalization for medical illness: pooled analysis from MAGELLAN and MARINER","volume":"10","author":"G E Raskob","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"S S Anand","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"ref48","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"S S Anand","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1055\/s-0037-1603929","article-title":"The IMPROVEDD VTE risk score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification","volume":"1","author":"C M Gibson","year":"2017","journal-title":"TH Open"},{"issue":"09","key":"ref50","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1160\/TH17-03-0168","article-title":"New paradigms in venous thromboprophylaxis of medically ill patients","volume":"117","author":"A C Spyropoulos","year":"2017","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection","volume":"19","author":"S Demoulin","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1778-1083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T23:02:57Z","timestamp":1661727777000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1778-1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":50,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2022,8,21]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1778-1083","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,21]]},"published":{"date-parts":[[2022,2,21]]}}}